Testing effectiveness (Phase 2)Study completedNCT01449461
What this trial is testing
Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)
Who this might be right for
Lymphoma, Large-Cell, AnaplasticCarcinoma, Non-Small-Cell Lung
Ariad Pharmaceuticals 137